Cas:581-89-5 2-Nitronaphthalene manufacturer & supplier

Chemical Name:2-Nitronaphthalene

CAS.NO:581-89-5

Synonyms:EINECS 209-474-5;MFCD00004055;2-Nitronaphthalene;Naphthalene, 2-nitro-;β-Nitronaphthalene

Molecular Formula:C₁₀H₇NO₂

Molecular Weight:173.168

HS Code:2904209090

Physical and Chemical Properties:

Melting point:65-73 °C

Boiling point:319.6±11.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.671

PSA:45.82000

Exact Mass:173.047684

LogP:3.18

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:2538

Packing Group:III

Contact us for information like EINECS 209-474-5 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,β-Nitronaphthalene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 209-474-5 Use and application,EINECS 209-474-5 technical grade,usp/ep/jp grade.

Related News: The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 2-Nitronaphthalene manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 2-Nitronaphthalene supplier The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 2-Nitronaphthalene vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 2-Nitronaphthalene factory The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.